Department of Chemistry, Sathyabama Institute of Science and Technology, Chennai 600119, India.
Department of Chemistry, Sathyabama Institute of Science and Technology, Chennai 600119, India.
Bioorg Chem. 2021 Sep;114:105094. doi: 10.1016/j.bioorg.2021.105094. Epub 2021 Jun 13.
Microtubule targeting agents that disrupt the dynamic functioning of the mitotic spindle are some of the best chemotherapeutic agents. Interruption of microtubule dynamics through polymerization or depolymerization causes cell arrest leading to apoptosis. We report a novel class of aroylhydrazones with anticancer properties. Tubulin inhibition studies were performed using both computational and biological methods. Docking and pharmacophore mapping showed efficient binding between the ligands and the protein. Tubulin inhibition assay showed the aroylhydrazones to be inhibitors of tubulin polymerization. DFT studies explains the geometrical and electronic properties of the compounds. Furthermore, anticancer studies using lung and liver cancer cell lines gave low IC values with the methyl substituted hydrazone MH-2 being the most potent. (IC of 0.0896 and 0.1040 µM respectively). The methyl group is responsible for the effective binding to the protein. Thus, a new class of tubulin binding agents have been identified as potential agents in cancer therapy.
微管靶向剂可破坏有丝分裂纺锤体的动态功能,是最好的化疗药物之一。通过聚合或解聚来中断微管动力学会导致细胞停滞并引发细胞凋亡。我们报告了一类具有抗癌特性的新型芳酰腙。使用计算和生物学方法进行微管蛋白抑制研究。对接和药效团映射显示配体与蛋白质之间具有有效的结合。微管蛋白抑制试验表明芳酰腙是微管蛋白聚合抑制剂。DFT 研究解释了化合物的几何和电子性质。此外,使用肺癌和肝癌细胞系进行的抗癌研究显示出低的 IC 值,其中甲基取代的腙 MH-2 的活性最强(分别为 0.0896 和 0.1040 μM)。甲基是与蛋白质有效结合的原因。因此,已将一类新的微管结合剂鉴定为癌症治疗的潜在药物。